Senti Biosciences Holdings, Inc. (SNTI) stock
SNTINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.10−0.04 (-28.68%)
Close on Nov 17, 2026Market cap $3.02MP/E –Yield –
Senti Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Senti Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $31.32M, down 12.3% year over year. For fiscal 2025 it was $37.59M, up 9.4% from the year before. The highest annual figure on record is $37.59M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.59M | +9.4% |
| FY2024 | Dec 31, 2024 | $34.36M | +6.9% |
| FY2023 | Dec 31, 2023 | $32.15M | +14.2% |
| FY2022 | Dec 31, 2022 | $28.15M | +28.2% |
| FY2021 | Dec 31, 2021 | $21.96M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.77M | -22.6% |
| Q1 FY2026 | Mar 31, 2026 | $5.28M | -43.1% |
| Q4 FY2025 | Dec 31, 2025 | $7.76M | -0.2% |
| Q3 FY2025 | Sep 30, 2025 | $10.52M | +21.5% |
| Q2 FY2025 | Jun 30, 2025 | $10.03M | +9.6% |
| Q1 FY2025 | Mar 31, 2025 | $9.28M | +5.7% |
| Q4 FY2024 | Dec 31, 2024 | $7.77M | -14.8% |
| Q3 FY2024 | Sep 30, 2024 | $8.66M | -4.8% |
| Q2 FY2024 | Jun 30, 2024 | $9.15M | +33.1% |
| Q1 FY2024 | Mar 31, 2024 | $8.78M | +24.4% |
| Q4 FY2023 | Dec 31, 2023 | $9.12M | +29.6% |
| Q3 FY2023 | Sep 30, 2023 | $9.09M | +39.5% |
| Q2 FY2023 | Jun 30, 2023 | $6.88M | -25.6% |
| Q1 FY2023 | Mar 31, 2023 | $7.06M | -7.2% |
| Q4 FY2022 | Dec 31, 2022 | $7.04M | +9.8% |
| Q3 FY2022 | Sep 30, 2022 | $6.52M | +20.5% |
| Q2 FY2022 | Jun 30, 2022 | $9.25M | +76.6% |
| Q1 FY2022 | Mar 31, 2022 | $7.60M | – |
| Q4 FY2021 | Dec 31, 2021 | $6.41M | – |
| Q3 FY2021 | Sep 30, 2021 | $5.41M | – |
| Q2 FY2021 | Jun 30, 2021 | $5.24M | – |
See a number that looks wrong?